Altimmune
ALT
39 hedge funds and large institutions have $36.2M invested in Altimmune in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.
931% more call options, than puts
Call options by funds: $299K | Put options by funds: $29K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
5% more funds holding
Funds holding: 37 → 39 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
2% less capital invested
Capital invested by funds: $37M → $36.2M (-$834K)
Top Buyers
Top Sellers
ALT Hedge Fund Activity: Q1 2014 in Review
39 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2014, worth a combined $36.2M — down 2.3% from $37M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ALT positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $228K. The largest seller was Jet Capital Investors, cutting an estimated $389K.
- 39 institutional investors held Altimmune (ALT) as of Q1 2014, up from 37 in Q4 2013.
- Funds reported $36.2M of Altimmune stock for Q1 2014, down 2.3% quarter-over-quarter.
- 5 funds opened new Altimmune positions in Q1 2014 and 3 closed out, a net change of +2 holders.
- The largest Altimmune buyer in Q1 2014 was Vanguard Group, an estimated $228K added.
- The largest Altimmune seller in Q1 2014 was Jet Capital Investors, an estimated $389K sold.
Based on aggregated 13F filings for Q1 2014.